 |  |
| BISNIS-27 | ||
| 511.883 | ||
| -0.0370 | -0.0001% | |
| COMPOSITE | ||
| 6,731.079 | ||
| -3.7530 | -0.0006% | |
| DBX | ||
| 1,577.798 | ||
| -18.2040 | -0.0114% | |
| I-GRADE | ||
| 209.600 | ||
| -0.2600 | -0.0012% | |
| IDX30 | ||
| 416.107 | ||
| -1.0280 | -0.0025% | |
| IDX80 | ||
| 118.764 | ||
| -0.4600 | -0.0039% | |
| IDXBUMN20 | ||
| 346.229 | ||
| 0.6090 | 0.0018% | |
| AUDRP | ||
| 10,925.100 | ||
| 15.7000 | 0.1439% | |
| EURRP | ||
| 17,536.900 | ||
| 12.3000 | 0.0702% | |
| JPYRP | ||
| 102.250 | ||
| 0.1910 | 0.1871% | |
| RP | ||
| 16,405.000 | ||
| -5.0000 | -0.0305% | |
| SINRP | ||
| 12,086.700 | ||
| 13.4000 | 0.1110% | |
Kandidat obat oral untuk pasien COVID-19 bertambah dengan kehadiran pil antivirus Paxlovid. Berdasarkan hasil sementara uji klinis fase II/III, Paxlovid menunjukkan hasil yang baik sehingga segera diajukan untuk mendapatkan izin penggunaan darurat.
